Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis

Objective: Aberrations in the PI3K/AKT/mTOR survival pathway in many cancers are the most common genomic abnormalities. The phytochemical and bioactive agent sulforaphane (SFN) has nutrigenomic potential in activating the expression of several cellular protective genes via the transcription factor n...

Descripción completa

Detalles Bibliográficos
Autores principales: Mokhtari, Reza Bayat, Qorri, Bessi, Baluch, Narges, Sparaneo, Angelo, Fabrizio, Federico Pio, Muscarella, Lucia Anna, Tyker, Albina, Kumar, Sushil, Cheng, Hai-Ling Margaret, Szewczuk, Myron R., Das, Bikul, Yeger, Herman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310668/
https://www.ncbi.nlm.nih.gov/pubmed/34316328
http://dx.doi.org/10.18632/oncotarget.28011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310668/
https://www.ncbi.nlm.nih.gov/pubmed/34316328
http://dx.doi.org/10.18632/oncotarget.28011

Ejemplares similares